Kestra Medical Technologies Ltd (KMTS) Q4 2026 Earnings Call Highlights: Record Revenue Growth ...

Despite a significant net loss, Kestra Medical Technologies Ltd (KMTS) reports robust revenue growth and strategic advancements in sales territories and product innovation.

This article first appeared on GuruFocus. - Revenue: $28.6 million for Q4, a 66% increase year-over-year; $95 million for FY26, a 59% increase compared to FY25. - Gross Margin: 54.8% for Q4, expanded by over 10 points year-over-year and 200 basis points sequentially; 51.4% for FY26, increased by approximately 11 points compared to FY25. - Operating Expenses: $55 million GAAP operating expenses for Q4; $44.7 million excluding nonrecurring costs and stock-based compensation.

- Net Loss: $38.8 million GAAP net loss for Q4, compared to $51.1 million in the prior-year period. - Adjusted EBITDA Loss: $26.7 million for Q4, compared to $20.3 million in the prior-year period. - Cash and Investments: $262 million as of April 30.

- Operating Cash Burn: $18.7 million net cash used in operating activities for Q4, reduced from $24.1 million in the prior-year period. - Sales Territories: Approximately 130 active sales territories at the end of FY26, up from about 80 at the end of FY25. - FY27 Revenue Guidance:

Expected revenue of $137 million, a 44% increase compared to FY26. Release Date: July 14, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points - Kestra Medical Technologies Ltd (NASDAQ:KMTS) reported a 66% increase in revenue for the fourth quarter, reaching $28.6 million, driven by a 63% year-over-year increase in prescriptions. - The company achieved a gross margin of 54.8%, marking the tenth consecutive quarter of sequential gross margin expansion. - KMTS expanded its sales territories from 80 to 130, enhancing its market penetration and sales force productivity.

- The ASSURE system's clinical evidence and innovation, including a new detection algorithm, have strengthened its competitive position in the wearable cardioverter defibrillator (WCD) market. - KMTS secured a $200 million term loan facility, providing financial flexibility to invest in growth opportunities and potential acquisitions.

Negative Points - Despite strong revenue growth, KMTS reported a GAAP net loss of $38.8 million for the fourth quarter. - Operating expenses increased to $55 million, primarily due to investments in the commercial organization and revenue cycle management capabilities. - The company's adjusted EBITDA loss widened to $26.7 million in the fourth quarter compared to the prior-year period.

- KMTS's operating cash burn, although reduced, remains significant at $18.7 million for the fourth quarter. - The company faces challenges in fully penetrating existing territories, with some sales reps managing an unmanageable number of accounts.